Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension

Abstract

A previous study has shown that shorter bevacizumab infusions (0.5 mg/kg/min) can be safely administered without increasing the risk of infusion-related hypersensitivity reactions (HSRs). However, the risk of proteinuria and hypertension in patients receiving shorter infusions of bevacizumab is undetermined. This was a multicenter, prospective, observational study in patients receiving N = 120, 1347 infusions) receiving standard duration infusions of bevacizumab. Shorter bevacizumab infusions (0.5 mg/kg/min) do not increase the risk of proteinuria and hypertension.